Elevara Medicines

Elevara Medicines is a clinical-stage biotech company founded in 2025 and headquartered in London, UK, developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases. Its lead asset ELV001 is a first-in-class oral CDK4/6 inhibitor that targets the proliferation and inflammatory signalling of synovial fibroblasts — the cells driving persistent joint damage — rather than suppressing the immune system. ELV001 is designed to synergize with existing standard-of-care DMARDs and TNF inhibitors, offering a potential path to remission for the roughly 50% of RA patients who achieve only partial responses. The company's Phase 2b START-SYNERGY trial dosed its first patient in March 2026 across sites in the US, South Africa, and Europe.